Jones Lang LaSalle Inc vs Dr. Reddy's Laboratories Ltd Common Stock — how do they compare? Jones Lang LaSalle Inc trades at $294.36 (market cap $13.73B), while Dr. Reddy's Laboratories Ltd Common Stock trades at $12.75 (market cap $10.78B). The key difference: Jones Lang LaSalle Inc is the larger of the two by market cap, and Dr. Reddy's Laboratories Ltd Common Stock pays a 0.65% dividend while Jones Lang LaSalle Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Jones Lang LaSalle Inc for 71 Days and Dr. Reddy's Laboratories Ltd Common Stock for 0 Days on average.
| JLL | RDY | |
|---|---|---|
Market Cap | $13.73B | $10.78B |
Volume | 368,437 | 2,724,343 |
Sector | Real Estate | Health |
52-Week High | $392.79 | $15.38 |
52-Week Low | $280.16 | $11.38 |
Typical Hold Time | 71 Days | 0 Days |
Enterprise Value | $16.49B | $10.68B |
Dividend Yield | — | 0.65% |
Signals from Pluang's Aura AI — not financial advice
JLL trades at $295.25, down 0.96% on the day, reflecting near-term pressure amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, revenue growth from $20.9B in 2022 to $26.1B in 2025, and improving net margins. Recent acquisitions and strategic appointments highlight operational momentum, while analyst consensus remains bullish with a $450.50 price target.
The outlook is positive given valuation discounts (P/E 14.31, P/S 0.52) and robust cash flow growth, though risks include real estate market cyclicality and technical resistance near $297. Upside hinges on continued execution and sector tailwinds, supporting a constructive view for long-term investors.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →Dr. Reddy's Laboratories Ltd. develops and manufactures generic medicines, active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter (OTC) products, headquartered in Hyderabad, India, with therapeutic focus areas spanning gastrointestinal, cardiovascular, oncology, and dermatology.
Read more on RDY →